OR WAIT null SECS
May 02, 2025
Article
In this analysis, investigators highlight the efficacy and safety of azathioprine as a monotherapy for those with recalcitrant and severe alopecia areata.
May 01, 2025
In this iteration of our Month in Review series, we highlight some of the most notable stories covered in April in the dermatology field.
April 30, 2025
This analysis was a single-center retrospective cohort study, with investigators highlighting an underrecognized alopecia pattern.
This announcement by Q32 Bio Inc. highlights the Fast Track designation by the FDA granted to bempikibart (ADX-914) for alopecia areata.
April 29, 2025
These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.
April 28, 2025
These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.
April 25, 2025
In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.
April 24, 2025
These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.
April 23, 2025
In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.
Healthier hair and scalp according to Hair & Scalp CARE questionnaire responses was linked to lower levels of perceived stress and good sleep health.
